{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:15:43Z","timestamp":1778649343349,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Industrial Research Fund of the University of Antwerp, Belgium","award":["PS ID 32387"],"award-info":[{"award-number":["PS ID 32387"]}]},{"name":"Research Foundation, Flanders (FWO), Belgium","award":["1120816N"],"award-info":[{"award-number":["1120816N"]}]},{"name":"FWO","award":["K1C3718N"],"award-info":[{"award-number":["K1C3718N"]}]},{"name":"Royal Belgian Academy of Medicine"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jcv.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T22:59:17Z","timestamp":1557615557000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions"],"prefix":"10.1016","volume":"117","author":[{"given":"Severien","family":"Van Keer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Willhauck-Fleckenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Pattyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebren A.A.","family":"Tjalma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xaveer","family":"Van Ostade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niel","family":"Hens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Waterboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Vorsters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2019.05.004_bib0005","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion","volume":"195","author":"Plummer","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2019.05.004_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.jcv.2019.05.004_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/hv.22693","article-title":"Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination","volume":"9","author":"Scherpenisse","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jcv.2019.05.004_bib0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0897.2005.00267.x","article-title":"Immunologic uniqueness of the genital tract: challenge for vaccine development","volume":"53","author":"Mestecky","year":"2005","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.jcv.2019.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2019.05.004_bib0030","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djg018","article-title":"Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"95","author":"Nardelli-Haefliger","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jcv.2019.05.004_bib0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bpobgyn.2017.08.010","article-title":"Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage","volume":"47","author":"Brotherton","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.jcv.2019.05.004_bib0040","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2019.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials","volume":"17","author":"Arbyn","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jcv.2019.05.004_bib0050","series-title":"Worldwide Female and Male HPV Vaccination Coverage up to 2018. IPVC2018. Sydney","author":"Bruni","year":"2018"},{"key":"10.1016\/j.jcv.2019.05.004_bib0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/ijc.30092","article-title":"Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda","volume":"139","author":"Franceschi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2019.05.004_bib0060","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4161\/21645515.2014.995058","article-title":"The use of urine in the follow-up of HPV vaccine trials","volume":"11","author":"Vorsters","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jcv.2019.05.004_bib0065","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/jmv.22183","article-title":"Urine testing as a surveillance tool to monitor the impact of HPV immunization programs","volume":"83","author":"Cuschieri","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2019.05.004_bib0070","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1128\/JVI.06093-11","article-title":"A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection","volume":"85","author":"Longet","year":"2011","journal-title":"J. Virol."},{"issue":"Suppl 5","key":"10.1016\/j.jcv.2019.05.004_bib0075","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines--immune responses","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.jcv.2019.05.004_bib0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2019.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jcv.2019.05.004_bib0090","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/hv.36117","article-title":"Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jcv.2019.05.004_bib0095","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine","volume":"6","author":"Schwarz","year":"2010","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.jcv.2019.05.004_bib0100","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jmv.20901","article-title":"Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia","volume":"79","author":"Passmore","year":"2007","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2019.05.004_bib0105","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1158\/1055-9965.EPI-10-0184","article-title":"Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection","volume":"19","author":"Kemp","year":"2010","journal-title":"Cancer Epidem. Biomar."},{"key":"10.1016\/j.jcv.2019.05.004_bib0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-1759(99)00037-X","article-title":"Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures","volume":"225","author":"Hildesheim","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jcv.2019.05.004_bib0115","doi-asserted-by":"crossref","first-page":"g6252","DOI":"10.1136\/bmj.g6252","article-title":"Urine testing for HPV: rationale for using first void","volume":"349","author":"Vorsters","year":"2014","journal-title":"Bmj."},{"key":"10.1016\/j.jcv.2019.05.004_bib0120","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1373\/clinchem.2005.052381","article-title":"Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins","volume":"51","author":"Waterboer","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jcv.2019.05.004_bib0125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jim.2005.11.008","article-title":"Suppression of non-specific binding in serological Luminex assays","volume":"309","author":"Waterboer","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jcv.2019.05.004_bib0130","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"issue":"Pt 2","key":"10.1016\/j.jcv.2019.05.004_bib0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1099\/0022-1317-80-2-409","article-title":"Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16","volume":"80","author":"Bontkes","year":"1999","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jcv.2019.05.004_bib0140","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1158\/1055-9965.EPI-09-0348","article-title":"Determinants and correlation of systemic and cervical concentrations of total IgA and IgG","volume":"18","author":"Safaeian","year":"2009","journal-title":"Cancer Epidem. Biomar."},{"issue":"Suppl. 3","key":"10.1016\/j.jcv.2019.05.004_bib0145","article-title":"Prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2019.05.004_bib0150","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/jmv.23616","article-title":"Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme","volume":"85","author":"Mollers","year":"2013","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2019.05.004_bib0155","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1016\/j.vaccine.2018.02.002","article-title":"Options for design of real-world impact studies of single-dose vaccine schedules","volume":"36","author":"Franceschi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2019.05.004_bib0160","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/j.vaccine.2018.02.076","article-title":"HPV single-dose vaccination: impact potential, evidence base and further evaluation","volume":"36","author":"Stanley","year":"2018","journal-title":"Vaccine"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219301131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219301131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T14:35:09Z","timestamp":1563460509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653219301131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":32,"alternative-id":["S1386653219301131"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2019.05.004","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}